Skip to main content
Have a personal or library account? Click to login
AB-Kefir probiotics ameliorate dyslipidaemia and endothelial dysfunction in high-fat diet-induced obese rats Cover

AB-Kefir probiotics ameliorate dyslipidaemia and endothelial dysfunction in high-fat diet-induced obese rats

Open Access
|Nov 2026
Read online

References

  1. Abd-Alwahab, W., & Al-Dulaimi, F. (2018). Effects of kefir as a probiotic on total lipid profile and activity of aspartate amino transferase and alanine amino transferase in serum of human. Biochemical and Cellular Archives, 18, 411–414. https://doi.org/10.13140/RG.2.2.16238.25928
  2. Abdi, M., Esmaeili, H., Ghaleh, G., & Ranjbar, R. (2022). Lactobacilli and Bifidobacterium as anti-atherosclerotic agents. Iranian Journal of Basic Medical Sciences, 25, 934–946. https://doi.org/10.22038/IJBMS.2022.63860.14073
  3. Aggarwal, J., Swami, G., & Kumar, M. (2013). Probiotics and their effects on metabolic diseases: An update. Journal of Clinical and Diagnostic Research, 7, 173–177. https://doi.org/10.7860/JCDR/2012/5004.2701
  4. Akar, F., Sumlu, E., Alçığır, M.E., Bostancı, A., & Sadi, G. (2021). Potential mechanistic pathways underlying intestinal and hepatic effects of kefir in high-fructose-fed rats. Food Research International, 143, 110287. https://doi.org/10.1016/j.foodres.2021.110287
  5. Akther, F., Razan, R., Shaligram, S., Graham, J. L., Stanhope, K. L., Allen, K. N., Vázquez-medina, J. P., Havel, P. J., & Rahimian, R. (2021). Potentiation of acetylcholine-induced relaxation of aorta in male UC Davis type 2 diabetes mellitus (UCD-T2DM) rats: Sex-specific responses. Frontiers in Physiology, 12, 616317. https://doi.org/10.3389/fphys.2021.616317
  6. Angelis-Pereira, M. C. D., Barcelos, M. D. F. P., Sousa, M. S. B., & Pereira, J. D. A. R. (2013). Effects of the kefir and banana pulp and skin flours on hypercholesterolemic rats. Acta Cirurgica Brasileira, 28, 481–486. https://doi.org/10.1590/S0102-86502013000700001
  7. Asemi, Z., Zare, Z., Shakeri, H., Sabihi, S. S., & Esmaillzadeh, A. (2013). Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Annals of Nutrition and Metabolism, 63, 1–9. https://doi.org/10.1159/000349922
  8. Azemi, A. K., Mokhtar, S. S., Hou, L. J., Sharif, S. E. T., & Rasool, A. H. G. (2021). Model for type 2 diabetes exhibits changes in vascular function and structure due to vascular oxidative stress and inflammation. Biotechnic and Histochemistry, 96, 498–506. https://doi.org/10.1080/10520295.2020.1823480
  9. Azizi, N. F., Kumar, M. R., Yeap, S. K., Abdullah, J. O., Khalid, M., & Alitheen, N. B. (2021). Kefir and its biological activities. Foods, 10(6), 1210. https://doi.org/10.3390/foods10061210
  10. Bagi, Z., Feher, A., & Cassuto, J. (2012). Microvascular responsiveness in obesity: Implications for therapeutic intervention. British Journal of Pharmacology, 165, 544–560. https://doi.org/10.1111/j.1476-5381.2011.01606.x
  11. Bellikci-koyu, E., Sarer-yurekli, B. P., Karagozlu, C., Aydin-kose, F., Ozgen, A. G., & Buyuktuncer, Z. (2022). Probiotic kefir consumption improves serum apolipoprotein A1 levels in metabolic syndrome patients: A randomized controlled clinical trial. Nutrition Research, 102, 59–70. https://doi.org/10.1016/j.nutres.2022.02.006
  12. Bourrie, B. C. T., Willing, B. P., & Cotter, P. D. (2016). The microbiota and health promoting characteristics of the fermented beverage kefir. Frontiers in Microbiology, 7, 647. https://doi.org/10.3389/fmicb.2016.00647
  13. Bourrie, B. C. T., Cotter, P. D., & Willing, B. P. (2018). Traditional kefir reduces weight gain and improves plasma and liver lipid profiles more successfully than a commercial equivalent in a mouse model of obesity. Journal of Functional Foods, 46, 29–37. https://doi.org/10.1016/j.jff.2018.04.039
  14. Bourrie, B. C. T., Richard, C., & Willing, B. P. (2020). Kefir in the prevention and treatment of obesity and metabolic disorders. Current Nutrition Reports, 9, 184–192. https://doi.org/10.1007/s13668-020-00315-3
  15. Brasil, G. A., Silva-Cutini, M. A., Moraes, F. S. A., Pereira, T. M. C., Vasquez, E. C., Lenz, D., & de Andrade, T. U. (2018). The benefits of soluble non-bacterial fraction of kefir on blood pressure and cardiac hypertrophy in hypertensive rats are mediated by an increase in baroreflex sensitivity and decrease in angiotensin-converting enzyme activity. Nutrition, 51–52, 66–72. https://doi.org/10.1016/j.nut.2017.12.007
  16. Chen, H. L., Tsai, T. C., Tsai, Y. C., Liao, J. W., Yen, C. C., & Chen, C. M. (2016). Kefir peptides prevent high-fructose corn syrup-induced non- alcoholic fatty liver disease in a murine model by modulation of inflammation and the JAK2 signaling pathway. Nutrition & Diabetes, 6, e237. https://doi.org/10.1038/nutd.2016.49
  17. Chen, Y., Guan, W., Zhang, N., Wang, Y, Tian, Y., Sun, H., Li, X., Wang, Y, & Liu, J. (2022). Lactobacillus plantarum Lp2 improved LPS-induced liver injury through the TLR-4/MAPK/NFκB and Nrf2-HO-1/CYP2E1 pathways in mice. Food & Nutrition Research, 66, 5459. https://doi.org/10.29219/fnr.v66.5459
  18. Chen, Y.-T.; Hsu, A.-H., Chiou, S.-Y., Lin, Y.-C., & Lin, J.-S. (2021). AB-kefir reduced body weight and ameliorated inflammation in adipose tissue of obese mice fed a high-fat diet, but not a high-sucrose diet. Nutrients, 13, 2182. https://doi.org/10.3390/nu13072182
  19. Cheng, C., Tsai, S., Chiu, C., Pan, T., & Tsai, T. Y. (2013). The effect of probiotic-fermented soy milk on enhancing the NO-mediated vascular relaxation factors. Journal of Science and Food Agriculture, 93, 1219–1225. https://doi.org/10.1002/jsfa.5880
  20. Choi, J., Kang, H. W., Lim, W., Kim, M., Lee, I., & Cho, H. (2017). Kefir prevented excess fat accumulation in diet-induced obese mice. Bioscience Biotechnology and Biochemistry, 81, 958–965. https://doi.org/10.1080/09168451.2016.1258984
  21. Chong, B., Jayabaskaran, J., Jauhari, S. M., Chan, S. P., Goh, R., Kueh, M. T. W., Li, H., Chin, Y. H., Kong, G., Anand, V. V., Wang, J.-W., Muthiah, M., Jain, V., Mehta, A., Lim, S. L., Foo, R., Figtree, G. A., Nicholls, S. J., Mamas, M. A., Januzzi, J. L., Chew, N. W. S., Richards, A. M., & Chan, M. Y. (2025). Global burden of cardiovascular diseases: projections from 2025 to 2050. European Journal of Preventive Cardiology, 32, 1001–1115. https://doi.org/10.1093/eurjpc/zwae281
  22. Di Cesare, M., Perel, P., Taylor, S., Kabudula, C., Bixby, H., Gaziano, T. A., McGhie, D. V., Mwangi, J., Pervan, B., Narula, J., Pineiro, D., & Pinto, F. J. (2024). The heart of the world. Global Heart, 19, 11 https://doi.org/10.5334/gh.1288
  23. Dinh, Q., Drummond, G., Sobey, C., & Chrissobolis, S. (2014). Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. BioMed Research International, 2014, 406960. https://doi.org/10.1155/2014/406960
  24. Dixon, A., Robertson, K., Yung, A., Que, M., Randall, H., & Wellalagodage, D. (2020). Efficacy of probiotics in patients of cardiovascular disease risk: A systematic review and meta-analysis. Current Hypertension Reports, 22, 74. https://doi.org/10.1007/s11906-020-01080-y
  25. Ettinger, G., MacDonald, K., Reid, G., & Burton, J. (2014). The influence of the human microbiome and probiotics on cardiovascular health. Gut Microbes, 5, 719–728. https://doi.org/10.4161/19490976.2014.983775
  26. Farag, M. A., Jomaa, S. A., Abd El-Wahed, A., & El-Seedi, H. R. (2020). The many faces of kefir fermented dairy products: Quality characteristics, flavour chemistry, nutritional value, health benefits, and safety. Nutrients, 12, 346. https://doi.org/10.3390/nu12020346
  27. Friques, Andreia G. F., Arpini, C. M., Kalil, I. C., Gava, A. L., Leal, M. A., Porto, M. L., Nogueira, B. V., Dias, A. T., Andrade, T. U., Pereira, T. M. C., Meyrelles, S. S., Campagnaro, B. P., & Vasquez, E. C. (2015). Chronic administration of the probiotic kefir improves the endothelial function in spontaneously hypertensive rats. Journal of Translational Medicine, 13, 390. https://doi.org/10.1186/s12967-015-0759-7.
  28. Gao, J., Ding, G., Li, Q., Gong, L., Huang, J., & Sang, Y. (2019). Tibet kefir milk decreases fat deposition by regulating the gut microbiota and gene expression of Lpl and Angptl 4 in high fat diet-fed rats. Food Research International, 121, 278–287. https://doi.org/10.1016/j.foodres.2019.03.029
  29. Gómez-Guzmán, M., Toral, M., Romero, M., Jiménez, R., Galindo, P., Sánchez, M., Zarzuelo, M., Olivares, M., Gálvez, J., & Duarte, J. (2015). Antihypertensive effects of probiotics Lactobacillus strains in spontaneously hypertensive rats. Molecular Nutrition & Food Research, 59, 2326–2336. https://doi.org/10.1002/mnfr.201500290
  30. Hadisaputro, S., Djokomoeljanto, R. R. J., Judiono, & Soesatyo, M. H. N. E. (2012). The effects of oral plain kefir supplementation on proinflammatory cytokine properties of the hyperglycemia Wistar rats induced by streptozotocin. Acta Medica Indonesiana, 44(2), 100–104. https://pubmed.ncbi.nlm.nih.gov/22745139
  31. Hao, R., Liu, Q., Wang, L., Jian, W., Cheng, Y., Zhang, Q., Hayer, K., Kamarudin, R., Idris, R., Zhang, Y., Lu, H., & Tu, Z. (2023). Anti-inflammatory effect of Lactiplantibacillus plantarum T1 cell- free supernatants through suppression of oxidative stress and NF-κB- and MAPK-signaling pathways. Applied and Environmental Microbiology, 89, e00608-23. https://doi.org/10.1128/aem.00608-23
  32. Hariri, M., Salehi, R., Feizi, A., Mirlohi, M., Kamali, S., & Ghiasvand, R. (2015). The effect of probiotic soy milk and soy milk on anthropometric measures and blood pressure in patients with type II diabetes mellitus: a randomized double-blind clinical trial. ARYA Atherosclerosis, 11(Suppl 1), 74–80. https://pmc.ncbi.nlm.nih.gov/articles/PMC4530661
  33. Harisa, G., Taha, E., Khalil, A., & Salem, M. (2009). Oral administration of Lactobacillus acidophilus restores nitric oxide level in diabetic rats. Australian Journal of Basic and Applied Sciences, 3(3), 2963–2969.
  34. Judiono, J., Hadisaputro, S., Ks, I., Cahyono, B., & Suzery, M. (2014). Effects of clear kefir on biomolecular aspects of glycemic status of type 2 diabetes mellitus (T2DM) patients in Bandung, West Java [Study on human blood glucose, c peptide and insulin]. Functional Foods in Health and Disease, 4, 340–348. https://doi.org/10.31989/ffhd.v4i8.145
  35. Katsiki, N., Mikhailidis, D., & Mantzoros, C. (2016). Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism, 65, 1109–1123. https://doi.org/10.1016/j.metabol.2016.05.003
  36. Kim, D. H., Kim, H., Jeong, D., Kang, I. B., Chon, J. W., Kim, H. S., Song, K. Y., & Seo, K. H. (2017). Kefir alleviates obesity and hepatic steatosis in high-fat diet-fed mice by modulation of gut microbiota and mycobiota: targeted and untargeted community analysis with correlation of biomarkers. Journal of Nutritional Biochemistry, 44, 35–43. https://doi.org/10.1016/j.jnutbio.2017.02.014
  37. Kim, S. H., Cho, Y. K., Kim, Y. J., Jung, C. H., Lee, W. J., Park, J. Y., Huh, J. H., Kang, J. G., Lee, S. J., & Ihm, S. (2022). Association of the atherogenic index of plasma with cardiovascular risk beyond the traditional risk factors: A nationwide population-based cohort study. Cardiovascular Diabetology, 21, 81. https://doi.org/10.1186/s12933-022-01522-8
  38. Kobayashi, T., Taguchi, K., Yasuhiro, T., Matsumoto, T., & Kamata, K. (2004). Impairment of PI3-K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model. Hypertension, 44(6), 956–962. https://doi.org/10.1161/01.HYP.0000147559.10261.a7
  39. Kopin, L., & Lowenstein, C. (2017). Dyslipidemia. Annals of Internal Medicine, 167, ITC81–ITC96. https://doi.org/10.7326/aitc201712050
  40. Lye, H., Rusul, G., & Liong, M. (2010). Removal of cholesterol by Lactobacilli via incorporation and conversion to coprostanol. Journal of Dairy Science, 93, 1383–1392. https://doi.org/10.3168/jds.2009-2574
  41. Malik, M., Suboc, T. M., Tyagi, S., Salzman, N., Wang, J., Ying, R., Tanner, M. J., Kakarla, M., Baker, J. E., & Widlansky, M. E. (2018). Lactobacillus plantarum 299v supplementation improves vascular endothelial function and reduces inflammatory biomarkers in med with stable coronary artery disease. Circulation Research, 123(9), 1091–1102. https://doi.org/10.1161/circresaha.118.313565
  42. Mazloom, Z., Yousefinejad, A., & Dabbaghmanesh, M. (2013). Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: A clinical trial. Iranian Journal of Medical Science, 38(1), 38–43. https://pubmed.ncbi.nlm.nih.gov/23645956
  43. Mehta, D., Ravindran, K., & Kuebler, W. (2014). Novel regulators of endothelial barrier function. American Journal of Physiology, 307(12), L924–L935. https://doi.org/10.1152/ajplung.00318.2014
  44. Miremadi, F., Ayyash, M., Sherkat, F., & Stojanovska, L. (2014). Cholesterol reduction mechanisms and fatty acid composition of cellular membranes of probiotic Lactobacilli and Bifidobacteria. Journal of Functional Foods, 9, 295–305. https://doi.org/10.1016/j.jff.2014.05.002
  45. Mlinar, B., Marc, J., Janez, A., & Pfeifer, M. (2007). Molecular mechanisms of insulin resistance and associated diseases. Clinica Chimica Acta, 375(1–2), 20–35. https://pubmed.ncbi.nlm.nih.gov/16956601
  46. Mokhtar, S. S., Vanhoutte, P. M., Leung, S. W. S., Suppian, R., Yusof, M. I., & Rasool, A. H. G. (2016). Reduced nitric oxide-mediated relaxation and endothelial nitric oxide synthase expression in the tail arteries of streptozotocin-induced diabetic rats. European Journal of Pharmacology, 773, 78–84. https://doi.org/10.1016/j.ejphar.2016.01.013
  47. Mutalub, Y. B., Azemi, A. K., Suhaimi, S. Q. A., Rasool, A. H. G., Tang, S. P., Lee, C-C., & Mokhtar, S. S. (2025). AB-kefir modulates gut microbiota and ameliorates obesity, metabolic and vascular insulin resistance in high-fat diet-induced obese rats. Journal of Functional Foods, 128, 106802. https://doi.org/10.1016/j.jff.2025.106802
  48. Olas, B. (2020). Probiotics, prebiotics and symbiotics – A promising strategy in prevention and treatment of cardiovascular diseases? International Journal of Molecular Sciences, 21, 9737. https://doi.org/10.3390/ijms21249737
  49. Ostadrahimi, A., Taghizadeh, A., Mobasseri, M., Farrin, N., Payahoo, L., & Beyramalipoor, G. Z. (2015). Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial. Iranian Journal of Public Health, 44(2), 228–237. https://pubmed.ncbi.nlm.nih.gov/25905057
  50. Peluzio, M., Dias, M., Martinez, J., & Milagro, F. I. (2021). Kefir and intestinal microbiota modulation: Implications in human health. Frontiers in Nutrition, 8, 638740. https://doi.org/10.3389/fnut.2021.638740
  51. Pimenta, F. S., Luaces-Regueira, M., Ton, A. M., Campagnaro, B. P., Manue, C.-T., Pereira, T. M., & Vasquez, E. C. (2018). Mechanisms of action of kefir in chronic cardiovascular and metabolic diseases. Cellular Physiology and Biochemistry, 48(5), 1901–1914. https://doi.org/10.1159/000492511
  52. Qaisrani, Z. N., Lin, W. P., Lay, B. B., Phyo, K. Y., San, M. M., Awaeloh, N., Aunsorn, S., Pattanayaiying, R., Ayudthaya, P. S. N., Hongkulsup, C., Buntin, N., & Chusri, S. (2025). The impact of kefir consumption on inflammation, oxidative stress status, and metabolic-syndrome-related parameters in animal models: A systematic review and meta-analysis. Foods, 14(12), 2077. https://doi.org/10.3390/foods14122077
  53. Rosa, D. D., Grześkowiak, L. M., Ferreira, C. L. L. F., Fonseca, A. C. M., Reis, S. A., Dias, M. M., Siqueira, N. P., Silva, L. L., Neves, C. A., Oliveira, L. L., MacHado, A. B. F., & Peluzio, M. D. C. G. (2016). Kefir reduces insulin resistance and inflammatory cytokine expression in an animal model of metabolic syndrome. Food & Function, 7(8), 3390–3401. https://doi.org/10.1039/c6fo00339g
  54. Rosa, D. D., Dias, M. M. S., Grześkowiak, Ł. M., Reis, S. A., Conceição, L. L., & Peluzio, C. G. (2017). Milk kefir: Nutritional, microbiological and health benefits. Nutrition Research Reviews, 30(1), 82–96. https://doi.org/10.1017/S0954422416000275
  55. Samah, S., Ramasamy, K., Meng, S., & Fen, C. (2016). Probiotics for the management of type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 118, 172–182. https://doi.org/10.1016/j.diabres.2016.06.014
  56. Shehata, M., El Sohaimy, S., El-Sahn, M., & Youssef, M. (2016). Screening of isolated potential probiotic lactic acid bacteria for cholesterol lowering property and bile salt hydrolase activity. Annals of Agricultural Sciences, 61(1), 65–75. https://doi.org/10.1016/j.aoas.2016.03.001
  57. Silva, de A. M., Mowry, E. F., Peaden, C. S., Andrade, U. T., & Biancardi, C. V. (2020). Kefir ameliorates hypertension via gut–brain mechanisms in spontaneously hypertensive rats. Journal of Nutritional Biochemistry, 77, 108318. https://doi.org/10.1016/j.jnutbio.2019.108318
  58. Sotoudeh, N., & Namavar, M. R. (2022). Optimisation of ketamine-xylazine anaesthetic dose and its association with changes in the dendritic spine of CA1 hippocampus in the young and old male and female Wistar rats. Veterinary Medicine and Science, 8(6), 2545–2552. https://doi.org/10.1002/vms3.936
  59. St-Onge, M., Farnworth, E., & Jones, P. (2000). Consumption of fermented and nonfermented dairy products: effects on cholesterol concentrations and metabolism. American Journal of Clinical Nutrition, 71(3), 674–681. https://doi.org/10.1093/ajcn/71.3.674
  60. St-Onge, M.-P., Farnworth, E. R., Savard, T., Chabot, D., Mafu, A., & Jones, P. J. H. (2002). Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: A randomized controlled trial. BMC Complementary and Alternative Medicine, 2, 1–7. https://doi.org/10.1186/1472-6882-2-1
  61. Sun, J., & Buys, N. (2015). Effects of probiotics consumption on lowering lipids and CVD risk factors: a systematic review and meta-analysis of randomized controlled trials. Annals of Medicine, 47(6), 430–440. https://doi.org/10.3109/07853890.2015.1071872
  62. Tenorio-Jimenez, C., Martinez-Ramirez, M. J., Tercero-Lozano, M., Arraiza-Irigoyen, C., Del Castillo-Codes, I., Olza, J., Plaza-Diaz, J., Fontana, L., Migueles, J. H., & Olivares, M. (2018). Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: A randomized clinical trial (PROSIR). BMC Complementary and Alternative Medicine, 18(1), 306. https://pubmed.ncbi.nlm.nih.gov/30453950
  63. Toral, M., Gómez-Guzmán, M., & Jiménez, R. (2014). The probiotic Lactobacillus coryniformis CECT5711 reduces the vascular pro-oxidant and pro-inflammatory status in obese mice. Clinical Science, 127(1), 33–45. https://pubmed.ncbi.nlm.nih.gov/24410749
  64. Tripolt, N. J., Leber, B., Blattl, D., Eder, M., Wonisch, W., Scharnagl, H., & Stojakovic, T. (2013). Effect of supplementation with Lactobacillus casei on insulin sensitivity, β-cell function, and markers of endothelial function and inflammation in subjects with metabolic syndrome: A pilot study. Journal of Dairy Science, 96(1), 89–95. https://doi.org/10.3168/jds.2012-5863
  65. Tseng, C., & Chu, Y. (2025). Probiotics and phytoantioxidants target coronary endothelial dysfunction in irregular sleep- and obesity-associated cardiometabolic syndrome. Life, 15(11), 1740. https://doi.org/10.3390/life15111740
  66. Tung, Y.-T., Chen, H.-L., Wu, H.-S., Ho, M.-H., Chong, K.-Y., & Chen, C.-M. (2017). Kefir peptides prevent hyperlipidemia and obesity in high fat diet-induced obese rats via lipid metabolism modulation. Molecular Nutrition & Food Research, 62(3), 1700505. https://doi.org/10.1002/mnfr.201700505
  67. Underwood, W., & Anthony, R. (2020). AVMA guidelines for the euthanasia of animals: 2020 edition. American Veterinary Medical Association.
  68. Urdaneta, E., Barrenetxe, J., Aranguren, P., Irigoyen, A., Marzo, F., & Ibáñez, FC. (2007). Intestinal beneficial effects of kefir-supplemented diet in rats. Nutrition Research, 27(10), 653–658. https://doi.org/10.1016/j.nutres.2007.08.002
  69. Vasquez, E. C., Pereira, T. M. C., Campos-Toimil, M., Baldo, M. P., & Peotta, V. A. (2019). Gut microbiota, diet, and chronic diseases: The role played by oxidative stress. Oxidative Medicine and Cellular Longevity, 2019, 1–3. https://doi.org/10.1155/2019/7092032
  70. Vieira, C. P., Rosario, A. I. L. S., Lelis, C. A., Rekowsky, B. S. S., Carvalho, A. P. A., Rosário, D. K. A., Elias, T. A., Costa, M. P., Foguel, D., & Conte-Junior, C. A. (2021). Bioactive compounds from kefir and their potential benefits on health: A systematic review and meta-analysis. Oxidative Medicine and Cellular Longevity, 2021(1), 9081738. https://doi.org/10.1155/2021/9081738
  71. Vitheejongjaroen, P., Kasorn, A., Puttarat, N., Loison, F., & Taweechotipatr, M. (2022). Bifidobacterium animalis MSMC83 improves oxidative stress and gut microbiota in D-galactose-induced rats. Antioxidants, 11, 2146. https://doi.org/10.3390/antiox11112146
  72. Yadav, R., Khan, S. H., Mada, S. B., Meena, S., Kapila, R., & Kaila, S. (2019). Consumption of probiotic Lactobacillus fermentum MTCC: 5898-fermented milk attenuates dyslipidemia, oxidative stress, and inflammation in male rats fed on cholesterol-enriched diet. Probiotics and Antimicrobial Protein, 11, 509–518. https://doi.org/10.1007/s12602-018-9429-4
  73. Yilmaz, I., & Arslan, B. (2022). The effect of kefir consumption on the lipid profile for individuals with normal and dyslipidemic properties: A randomized controlled trial. Revista de Nutricao, 35, 210098. https://doi.org/10.1590/1678-9865202235e210098
  74. Yusuf, D., Nuraida, L., Dewanti-hariyadi, R., & Hunaefi, D. (2020). In vitro characterization of lactic acid bacteria from Indonesian kefir grains as probiotics with cholesterol-lowering effect. Journal of Microbiology and Biotechnology, 30(5), 726–732. https://doi.org/10.4014/jmb.1910.10028
  75. Zhang, Y., Du, R., Wang, L., & Zhang, H. (2010). The antioxidative effects of probiotic Lactobacillus casei Zhang on the hyperlipidemic rats. European Food Research and Technology, 231, 151–158. https://doi.org/10.1007/s00217-010-1255-1
DOI: https://doi.org/10.2478/aoas-2026-0028 | Journal eISSN: 2300-8733 (formerly 1642-3402) | Journal ISSN: 1642-3402
Language: English
Submitted on: Mar 1, 2026
Accepted on: Sep 22, 2026
Published on: Nov 11, 2026
Published by: National Research Institute of Animal Production
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2026 Yahkub Babatunde Mutalub, Ahmad Khusairi Azemi, Aida Hanum Ghulam Rasool, Tang Suk Peng, Lee Chia Chia, Siti Safiah Mokhtar, published by National Research Institute of Animal Production
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.